Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2014 Feb 28.
Published in final edited form as: Osteoarthritis Cartilage. 2013 Mar 6;21(5):643–645. doi: 10.1016/j.joca.2013.02.659

Insight into the function of DIO2, a susceptibility gene in human osteoarthritis, as an inducer of cartilage damage in a rat model: is there a role for chondrocyte hypertrophy?

MB Goldring †,‡,*
PMCID: PMC3937864  NIHMSID: NIHMS556692  PMID: 23473975

The detection of the relevant susceptibility genes has the promise to provide insight into underlying mechanisms of the development and progression of osteoarthritis (OA), and to point to new therapeutic strategies1. Early genetic studies on OA have provided evidence that several genes harbor OA susceptibility alleles including the growth differentiation factor 5 gene (GDF5)2,3, SMAD family member 3 (SMAD3)4, and the deiodinase iodothyronine type 2 and 3 genes (DIO2 and DIO3)5,6. More recently, Arthritis Research UK Osteoarthritis Genetics (arcOGEN), Translational REsearch in Europe Applied Technologies for OsteoArthritis (TREAT-OA), RAAK (Research Arthritis and Articular Cartilage), and other consortia have identified several OA-related quantitative trait loci by compiling genome wide association study (GWAS) data7,8,9,10,11. Since many of the OA susceptibility genes found by GWAS of blood cell samples are known to be involved in early skeletal development, the possibility that alterations in their expression or activity in the adult, and particularly in cartilage and bone where OA manifestation occurs, was proposed12.

The subject of a recent report byNagase et al.13, the OA susceptibility gene DIO2, encodes the deiodinase type 2 protein (D2), which is responsible for catalyzing the conversion of intracellular inactive thyroid hormone (T4) to its active form (T3). During normal growth plate development, active T3 subsequently signals the terminal maturation of the chondrocytes leading to cell hypertrophy, degradation and mineralization of the cartilage matrix, and bone formation14,15. DIO2 is among a number of OA susceptibility genes, including GDF5 and DOT1L, which are active in pathways during pre- and post-natal joint development leading to endochondral ossification12. Such findings have led to the notion that chondrocyte signaling events that take place in hypertrophic chondrocyte differentiation in the growth plate may reappear in the adult and lead to the development of OA in articular cartilage16, although this is controversial. When first identified, the DIO2 polymorphism was proposed to cause a deficiency of DIO2 and decreased thyroid hormone availability, impacting on cartilage matrix integrity, chondrocyte viability, and osteophyte formation5. Subsequent functional genomic studies have shown increased DIO2 gene expression and higher levels of protein in cartilage obtained from OA-affected compared to healthy joints17,18. These consequences were proposed to be due to imbalanced expression of the DIO2 risk allele at a 30% higher rate than the reference allele in OA compared to healthy cartilage17. Furthermore, the DIO2 susceptibility single nucleotide polymorphisms (SNPs) showed an association with hip joint geometry and OA susceptibility19, suggesting that variation in local T3 bioavailability in the growth plate may contribute to subtle variations in joint shape, which subsequently could influence biomechanical stability of the articular cartilage in aging individuals. In the context of skeletal development, it is of interest that Hedgehog-inducible WD repeat and SOCS box-containing protein 1 (WSB-1) modulates thyroid hormone activation and parathyroid hormone related protein (PTHrP) secretion20. Altered DIO2 activity in articular cartilage, therefore, may disrupt homeostasis by promoting hypertrophic chondrocyte differentiation and other adverse events that lead eventually to OA onset or progression5,12.

In the studies of Nagase et al.13, microarray analyses of human cartilage showed that DIO2 was expressed at levels of more than 2-fold higher in OA samples compared to healthy controls, whereas DIO1 was not detected and DIO3 was not significantly different. Also, they showed that Dio2 was expressed at higher levels than other deiodinase genes in articular cartilage of 8-week-old rats and that T3 treatment of cultured chondrocytes and cartilage explants isolated from these rats increased the gene expression of markers associated with chondrocyte hypertrophy and endochondral ossification, including alkaline phosphatase, type X collagen, osteocalcin, and Runx2, as reported previously by others2123. T3 also increased the expression of several cartilage matrix-degrading proteinases and enhanced the effects of interleukin (IL)-1α. The DIO2 gene is known to be upregulated by the pro-inflammatory nuclear factor (NF)-κB signaling pathway24, and the siRNA-mediated suppression of DIO2 was shown to increase IL-1β-induced expression of inflammatory mediators such as cyclooxygenase 2 (COX2) and IL-1β itself25. Thus, the consequences of the imbalanced deiodinase expression and activity will likely depend upon the availability of other upstream and downstream signals associated with inflammation and mechano-transduction. Also, discrepancies in findings of various studies may be due to differences among species, tissue sites, and age, as well as the models used.

The initial microarray and in vitro data presented by Nagase et al.13 provided the rationale for generating cartilage-specific Dio2 transgenic rats by Col2a1-driven expression of human (h) DIO2 in a bacterial artificial chromosome (BAC) construct. Since Dio2-deficient mice display no growth plate abnormality, the severe cartilage degradation due to surgically induced OA in rats with forced transgenic expression of hDIO2 in articular cartilage may reflect the pathological changes associated with upregulated expression in certain OA patients harboring the risk allele. Furthermore, this transgenic rat model will be a useful tool for further following up mechanisms associated with other factors involved in chondrocyte hypertrophy and OA, including HIF-2α, which the authors suggest may be regulated by T3, as well as those genes reflecting increased anabolism in late-stage OA, such as both type I collagen (COL1A1) and type II collagen (COL2A1) collagen genes, observed by Nagase et al.13 and in other microarray studies of human OA cartilage26,27.

In conclusion, the findings of the study by Nagase et al.13, by analyses in human and rat cartilage and in various culture models, take us a step closer to understanding the potential connection between DIO2 expression and chondrocyte hypertrophy in OA. The novel rat model, in which Col2a1-driven Dio2 overexpression resulted in enhanced cartilage degradation when the animals were challenged with surgically induced post-traumatic OA, however, did not define chondrocyte hypertrophy as the responsible event. Rather, the overexpression of Dio2 was associated with enhanced catabolic events consistent with the in vitro data showing that T3 induces several proteinase genes and enhances IL-1-induced gene expression. Whatever the precise mechanism, it is clear from this and other studies that imbalanced deiodinase regulation and activity in articular cartilage may lead to impaired cartilage tissue homeostasis and enhance the probability of development of osteoarthritis due to biomechanical trauma or aging.

Acknowledgment

Research related to this topic is supported by National Institutes of Health grants R01-AG022021 and RC4-AR060546.

Role of funding source

There was no funding for support of publication of this manuscript.

Footnotes

Author contributions

MBG is the sole author of this Editorial.

Conflict of interest

The author has no conflict of interest related to this work.

References

  • 1.Valdes AM, Spector TD. The clinical relevance of genetic susceptibility to osteoarthritis. Best Pract Res Clin Rheumatol. 2010;24:3–14. doi: 10.1016/j.berh.2009.08.005. [DOI] [PubMed] [Google Scholar]
  • 2.Chapman K, Takahashi A, Meulenbelt I, Watson C, Rodriguez-Lopez J, Egli R, et al. A meta-analysis of European and Asian cohorts reveals a global role of a functional SNP in the 5′ UTR of GDF5 with osteoarthritis susceptibility. Hum Mol Genet. 2008;17:1497–1504. doi: 10.1093/hmg/ddn038. [DOI] [PubMed] [Google Scholar]
  • 3.Evangelou E, Chapman K, Meulenbelt I, Karassa FB, Loughlin J, Carr A, et al. Large-scale analysis of association between GDF5 and FRZB variants and osteoarthritis of the hip, knee, and hand. Arthritis Rheum. 2009;60:1710–1721. doi: 10.1002/art.24524. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Valdes AM, Spector TD, Tamm A, Kisand K, Doherty SA, Dennison EM, et al. Genetic variation in the SMAD3 gene is associated with hip and knee osteoarthritis. Arthritis Rheum. 2010;62:2347–2352. doi: 10.1002/art.27530. [DOI] [PubMed] [Google Scholar]
  • 5.Meulenbelt I, Min JL, Bos S, Riyazi N, Houwing-Duistermaat JJ, van der Wijk HJ, et al. Identification of DIO2 as a new susceptibility locus for symptomatic osteoarthritis. Hum Mol Genet. 2008;17:1867–1875. doi: 10.1093/hmg/ddn082. [DOI] [PubMed] [Google Scholar]
  • 6.Meulenbelt I, Bos SD, Chapman K, van der Breggen R, Houwing-Duistermaat JJ, Kremer D, et al. Meta-analyses of genes modulating intracellular T3 bio-availability reveal a possible role for the DIO3 gene in osteoarthritis susceptibility. Ann Rheum Dis. 2011;70:164–167. doi: 10.1136/ard.2010.133660. [DOI] [PubMed] [Google Scholar]
  • 7.Identification of new susceptibility loci for osteoarthritis (arc-OGEN): a genome-wide association study. Lancet. 2012;380:815–823. doi: 10.1016/S0140-6736(12)60681-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Day-Williams AG, Southam L, Panoutsopoulou K, Rayner NW, Esko T, Estrada K, et al. A variant in MCF2L is associated with osteoarthritis. Am J Hum Genet. 2011;89:446–450. doi: 10.1016/j.ajhg.2011.08.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Panoutsopoulou K, Southam L, Elliott KS, Wrayner N, Zhai G, Beazley C, et al. Insights into the genetic architecture of osteoarthritis from stage 1 of the arcOGEN study. Ann Rheum Dis. 2011;70:864–867. doi: 10.1136/ard.2010.141473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Kerkhof HJ, Lories RJ, Meulenbelt I, Jonsdottir I, Valdes AM, Arp P, et al. A genome-wide association study identifies an osteoarthritis susceptibility locus on chromosome 7q22. Arthritis Rheum. 2010;62:499–510. doi: 10.1002/art.27184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Castano Betancourt MC, Cailotto F, Kerkhof HJ, Cornelis FM, Doherty SA, Hart DJ, et al. Genome-wide association and functional studies identify the DOT1L gene to be involved in cartilage thickness and hip osteoarthritis. Proc Natl Acad Sci USA. 2012;109:8218–8223. doi: 10.1073/pnas.1119899109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Bos SD, Slagboom PE, Meulenbelt I. New insights into osteoarthritis: early developmental features of an ageing-related disease. Curr Opin Rheumatol. 2008;20:553–559. doi: 10.1097/BOR.0b013e32830aba48. [DOI] [PubMed] [Google Scholar]
  • 13.Nagase H, Nagasawa Y, Tachida Y, Sakakibara S, Okutsu J, Suematsu N, et al. Deiodinase 2 upregulation demonstrated in osteoarthritis patients cartilage causes cartilage destruction in tissue-specific transgenic rats. Osteoarthritis Cartilage. 2013;21:514–523. doi: 10.1016/j.joca.2012.12.013. [DOI] [PubMed] [Google Scholar]
  • 14.Wang L, Shao YY, Ballock RT. Thyroid hormone-mediated growth and differentiation of growth plate chondrocytes involves IGF-1 modulation of beta-catenin signaling. J Bone Miner Res. 2010;25:1138–1146. doi: 10.1002/jbmr.5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Adams SL, Cohen AJ, Lassova L. Integration of signaling pathways regulating chondrocyte differentiation during endochondral bone formation. J Cell Physiol. 2007;213:635–641. doi: 10.1002/jcp.21262. [DOI] [PubMed] [Google Scholar]
  • 16.van der Kraan PM, van den Berg WB. Chondrocyte hypertrophy and osteoarthritis: role in initiation and progression of cartilage degeneration? Osteoarthritis Cartilage. 2012;20:223–232. doi: 10.1016/j.joca.2011.12.003. [DOI] [PubMed] [Google Scholar]
  • 17.Bos SD, Bovee JV, Duijnisveld BJ, Raine EV, van Dalen WJ, Ramos YF, et al. Increased type II deiodinase protein in OA-affected cartilage and allelic imbalance of OA risk polymorphism rs225014 at DIO2 in human OA joint tissues. Ann Rheum Dis. 2012;71:1254–1258. doi: 10.1136/annrheumdis-2011-200981. [DOI] [PubMed] [Google Scholar]
  • 18.Karlsson C, Dehne T, Lindahl A, Brittberg M, Pruss A, Sittinger M, et al. Genome-wide expression profiling reveals new candidate genes associated with osteoarthritis. Osteoarthritis Cartilage. 2010;18:581–592. doi: 10.1016/j.joca.2009.12.002. [DOI] [PubMed] [Google Scholar]
  • 19.Waarsing JH, Kloppenburg M, Slagboom PE, Kroon HM, Houwing-Duistermaat JJ, Weinans H, et al. Osteoarthritis susceptibility genes influence the association between hip morphology and osteoarthritis. Arthritis Rheum. 2011;63:1349–1354. doi: 10.1002/art.30288. [DOI] [PubMed] [Google Scholar]
  • 20.Dentice M, Bandyopadhyay A, Gereben B, Callebaut I, Christoffolete MA, Kim BW, et al. The Hedgehog-inducible ubiquitin ligase subunit WSB-1 modulates thyroid hormone activation and PTHrP secretion in the developing growth plate. Nat Cell Biol. 2005;7:698–705. doi: 10.1038/ncb1272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Alini M, Kofsky Y, Wu W, Pidoux I, Poole AR. In serum-free culture thyroid hormones can induce full expression of chondrocyte hypertrophy leading to matrix calcification. J Bone Miner Res. 1996;11:105–113. doi: 10.1002/jbmr.5650110115. [DOI] [PubMed] [Google Scholar]
  • 22.Ballock RT, Reddi AH. Thyroxine is the serum factor that regulates morphogenesis of columnar cartilage from isolated chondrocytes in chemically defined medium. J Cell Biol. 1994;126:1311–1318. doi: 10.1083/jcb.126.5.1311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Wang L, Shao YY, Ballock RT. Thyroid hormone interacts with the Wnt/beta-catenin signaling pathway in the terminal differentiation of growth plate chondrocytes. J Bone Miner Res. 2007;22:1988–1995. doi: 10.1359/jbmr.070806. [DOI] [PubMed] [Google Scholar]
  • 24.Zeold A, Doleschall M, Haffner MC, Capelo LP, Menyhert J, Liposits Z, et al. Characterization of the nuclear factor-kappa B responsiveness of the human dio2 gene. Endocrinology. 2006;147:4419–4429. doi: 10.1210/en.2005-1608. [DOI] [PubMed] [Google Scholar]
  • 25.Cheng AW, Bolognesi M, Kraus VB. DIO2 modifies inflammatory responses in chondrocytes. Osteoarthritis Cartilage. 2012;20:440–445. doi: 10.1016/j.joca.2012.02.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Aigner T, Fundel K, Saas J, Gebhard PM, Haag J, Weiss T, et al. Large-scale gene expression profiling reveals major pathogenetic pathways of cartilage degeneration in osteoarthritis. Arthritis Rheum. 2006;54:3533–3544. doi: 10.1002/art.22174. [DOI] [PubMed] [Google Scholar]
  • 27.Ijiri K, Zerbini LF, Peng H, Otu HH, Tsuchimochi K, Otero M, et al. Differential expression of GADD45beta in normal and osteoarthritic cartilage: potential role in homeostasis of articular chondrocytes. Arthritis Rheum. 2008;58:2075–2087. doi: 10.1002/art.23504. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES